Amanta Healthcare Limited IPO Opens on September 01, 2025

POSTED BY: ANGHA SAKPAL, AUGUST 24 , 2025     

• Total Issue Size – Up To 1,00,00,000 Equity Shares of face value ₹ 10 each
• IPO Size – ₹ 12,600.00 Lakhs (At Upper Price Band)
• Price Band – ₹ 120 – ₹ 126 Per Share
• Lot Size – 119 Equity Shares

Mumbai,(RMN)  – Amanta Healthcare Limited, a pharmaceutical company engaged in development, manufacturing, and marketing of sterile liquid products, including both large and small volume parenterals (LVPs and SVPs), proposes to open its Initial Public Offering on September 01, 2025, aiming to raise ₹ 12,600.00 Lakhs (at upper price band) with shares to be listed on the NSE and BSE Platform.

The issue size is up to 1,00,00,000 equity shares with a face value of ₹ 10 each with a price band of ₹ 120 – ₹ 126 Per Equity Share.

Equity Share Allocation

• Qualified Institutional Buyer – Not more than 50,00,000 Equity Shares
• Non-Institutional Investors – Not less than 15,00,000 Equity Shares
• Individual Investors – Not less than 35,00,000 Equity Shares

The net proceeds from the IPO will be utilized for funding capital expenditure requirements for civil construction work and towards purchase of equipment, plant and machinery for setting up new manufacturing line of SteriPort at Hariyala, Kheda, Gujarat, funding capital expenditure requirements towards civil construction work, purchase of equipment, plant and machinery for setting up new manufacturing line for SVP at Hariyala, Kheda, Gujarat, and general corporate purposes. The anchor portion will open on Friday, August 29, 2025 and issue will close on Wednesday, September 03, 2025.

The Book Running Lead Manager to the Issue is Beeline Capital Advisors Private Limited, and the Registrar is MUFG Intime India Private Limited (Formerly Known as Link Intime India Private Limited).

Mr. Bhavesh Patel, Chairman and Managing Director of Amanta Healthcare Limited expressed,“Our company has grown by developing and supplying a wide range of sterile liquid products across therapeutic segments and medical devices. We have established a presence across domestic and international markets. This IPO marks a step forward in our growth journey, allowing us to expand our manufacturing capabilities with new SteriPort and SVP lines at our Hariyala facility, which will strengthen our capacity and support us for Future plans.”
About Amanta Healthcare Limited

Amanta Healthcare Limited, a pharmaceutical company engaged in developing, manufacturing, and marketing of sterile liquid products, including both large and small volume parenterals (LVPs and SVPs) using Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM) technologies, The Company serve’s six therapeutic segments such as fluid therapy – (IV Fluid), formulations, diluents, ophthalmic, respiratory care and irrigation solutions.

The company also manufacture medical devices like irrigation solutions, first-aid products, and eye lubricants. Our packaging includes a wide range of closure systems and container volumes from 2 ml to 1000 ml.

Amanta is led by experienced Management including Mr. Bhavesh Patel who is the Promoter, chairman and managing director of the company–. He is a Mechanical Engineer and holds a master’s degree in management with more than 30 years of experience.

In FY25, The Company achieved a Revenue of ₹ 27,470.82 Lakhs, EBITDA of ₹ 6,105.37 Lakhs & PAT of ₹ 1,050.07 Lakhs.

Disclaimer:

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.